AU Patent

AU2020321955A1 — HDAC6 inhibitors and uses thereof

Assigned to Eikonizo Therapapeutics Inc · Expires 2022-03-17 · 4y expired

What this patent protects

Provided herein are compounds that inhibit HDAC6, a protein whose activity is associated with a variety of diseases (

USPTO Abstract

Provided herein are compounds that inhibit HDAC6, a protein whose activity is associated with a variety of diseases (

Drugs covered by this patent

Patent Metadata

Patent number
AU2020321955A1
Jurisdiction
AU
Classification
—
Expires
2022-03-17
Drug substance claim
No
Drug product claim
No
Assignee
Eikonizo Therapapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.